Y
Yuankai Shi
Researcher at Peking Union Medical College
Publications - 8
Citations - 127
Yuankai Shi is an academic researcher from Peking Union Medical College. The author has contributed to research in topics: Mantle cell lymphoma & Chemotherapy. The author has an hindex of 4, co-authored 8 publications receiving 60 citations.
Papers
More filters
Journal ArticleDOI
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial
Matthew J. Matasar,Marcelo Capra,Muhit Ozcan,Fangfang Lv,Wei Li,Eduardo Yanez,Katya Sapunarova,T. Lin,Jie Jin,Wojciech Jurczak,Aryan Hamed,Ming-Chung Wang,Ross Baker,Igor Bondarenko,Qingyuan Zhang,Jifeng Feng,Klaus Geissler,Mihaela Lazaroiu,Güray Saydam,Árpád Szomor,Krimo Bouabdallah,Rinat Galiulin,Toshiki Uchida,Lidia Mongay Soler,Anjun Cao,Florian Hiemeyer,Aruna Mehra,Barrett H. Childs,Yuankai Shi,Pier Luigi Zinzani +29 more
TL;DR: In this article, copanlisib was combined with rituximab to improve progression-free survival in patients with relapsed indolent non-Hodgkin lymphoma.
Journal ArticleDOI
A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma.
Michael Wang,Liang Zhang,Xiaohong Han,Xiaohong Han,Jing Yang,Jianfei Qian,Sungyoul Hong,Pei Lin,Yuankai Shi,Jorge E. Romaguera,Larry W. Kwak,Qing Yi +11 more
TL;DR: This is the first human primary MCL animal model that should be useful for the biological and therapeutic research on MCL.
Journal ArticleDOI
Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Chemotherapy-Induced Neutropenia in Adults With Non-Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial
Douglas W. Blayney,Qingyuan Zhang,Jifeng Feng,Yanqiu Zhao,Igor Bondarenko,Ihor Vynnychenko,Nadezhda Kovalenko,Santosh Nair,Emad Ibrahim,Dmitriy Petrovich Udovista,Ramon Mohanlal,Stephan Ogenstad,Ene Ette,Lihua Du,Lan Huang,Yuankai Shi +15 more
TL;DR: Single dose-per-cycle plinabulin has a similar neutropenia protection benefit as pegfilgrastim, and bone pain reduction, thrombocytopenia reduction, and quality of life maintenance will be secondary end points.
Journal ArticleDOI
Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M-positive Non-Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study.
Ligang Xing,Yueyin Pan,Yuankai Shi,Yongqian Shu,Jifeng Feng,Wei Li,Lejie Cao,Lifeng Wang,Wei Gu,Yong Song,Puyuan Xing,Yutao Liu,Wen Gao,Jiuwei Cui,Nana Hu,Rutian Li,Hua Bao,Yang Shao,Jinming Yu +18 more
TL;DR: Osimertinib had potent activity against EGFR-T790M–positive NSCLC with CNS metastases and dynamic monitoring of plasma EGFR may suffice for predicting clinical responses, mitigating the need for repeat CSF biopsy.
Journal Article
Bortezomib is synergistic with rituximab and cyclophosphamide in inducing apoptosis of mantle cell lymphoma cells in vitro and in vivo
Michael Wang,Xiaohong Han,Liang Zhang,Luhong Sun,Jing Yang,Jianfei Qian,Larry W. Kwak,Jorge E. Romaguera,Yuankai Shi,Qing Yi +9 more
TL;DR: In this article, the authors evaluated whether BTZ is additive or synergistic with cyclophosphamide (CTX) and rituximab (RTX) for relapsed mantle cell lymphoma.